Karyopharm Therapeutics (25K0) Technical Analysis
Technical Sentiment
Overall ConsensusNeutral
10Bearish
4Neutral
8Bullish
Technical Analysis ConsensusSell
4Bearish
4Neutral
2Bullish
Moving Average ConsensusNeutral
6Bearish
0Neutral
6Bullish
1 Day timeframe · Data as of Oct 30, 2026
- Karyopharm Therapeutics’s (25K0) Moving Averages Convergence Divergence (MACD) indicator is -0.18, suggesting Karyopharm Therapeutics is a Sell.
- Karyopharm Therapeutics’s (25K0) 20-Day exponential moving average is EUR 0.59, while Karyopharm Therapeutics’s (25K0) share price is EUR 0.67, making it a Buy.
- Karyopharm Therapeutics’s (25K0) 50-Day exponential moving average is EUR 1.31, while Karyopharm Therapeutics’s (25K0) share price is EUR 0.67, making it a Sell.
Karyopharm Therapeutics (25K0) Pivot Points
1 Day timeframe · Data as of Oct 30, 2026
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Classic | 0.64 | 0.66 | 0.69 | 0.71 | 0.75 | 0.77 | 0.80 |
| Fibonacci | 0.66 | 0.68 | 0.69 | 0.71 | 0.73 | 0.75 | 0.77 |
Karyopharm Therapeutics (25K0) Moving Averages
1 Day timeframe · Data as of Oct 30, 2026
| Period | Simple | Exponential |
|---|---|---|
| MA5 | 0.52Buy | 0.56Buy |
| MA10 | 0.45Buy | 0.51Buy |
| MA20 | 0.45Buy | 0.59Buy |
| MA50 | 1.03Sell | 1.31Sell |
| MA100 | 3.40Sell | 2.63Sell |
| MA200 | 5.00Sell | 4.00Sell |
- Karyopharm Therapeutics’s (25K0) 10-Day exponential moving average is EUR 0.51, while Karyopharm Therapeutics’s (25K0) share price is EUR 0.67, making it a Buy.
- Karyopharm Therapeutics’s (25K0) 100-Day exponential moving average is EUR 2.63, while Karyopharm Therapeutics’s (25K0) share price is EUR 0.67, making it a Sell.
- Karyopharm Therapeutics’s (25K0) stock price is EUR 0.67 and Karyopharm Therapeutics’s (25K0) 50-day simple moving average is EUR 1.03, creating a Sell signal.
- Karyopharm Therapeutics’s (25K0) stock price is EUR 0.67 and Karyopharm Therapeutics’s (25K0) 100-day simple moving average is EUR 3.40, creating a Sell signal.
- Karyopharm Therapeutics’s (25K0) stock price is EUR 0.67 and Karyopharm Therapeutics’s (25K0) 200-day simple moving average is EUR 5.00, creating a Sell signal.
Karyopharm Therapeutics (25K0) Technical Indicators
1 Day timeframe · Data as of Oct 30, 2026
| Name | Value | Implied Action |
|---|---|---|
| RSI (14) | 47.92 | Neutral |
| STOCH (9,6) | 81.51 | Sell |
| STOCHRSI (14) | 79.65 | Neutral |
| MACD (12,26) | -0.18 | Sell |
| ADX (14) | 42.13 | Neutral |
| Williams %R | -13.77 | Sell |
| CCI (14) | 137.38 | Sell |
| ATR (14) | 0.09 | - |
| Ultimate Oscillator | 61.10 | Neutral |
| ROC | 36.27 | Buy |
- Karyopharm Therapeutics’s (25K0) Relative Strength Index (RSI) is 47.92, creating a Neutral signal.
- Karyopharm Therapeutics’s (25K0) Trend Strength Indicator (ADX) is 42.13, creating a Neutral signal.
- Karyopharm Therapeutics’s (25K0) Commodity Channel Index (CCI) is 137.38, creating a Sell signal.
- Karyopharm Therapeutics’s (25K0) Price Rate of Change (ROC) is 36.27, creating a Buy signal.
unique trading strategy with a flexible screenerTry it Now!
FAQ
Is 25K0 a Buy, Hold, or Sell?
Based on 25K0’s technical indicators on the 1-day timeframe as of Oct 30, 2026, 25K0 is a Hold.
What is 25K0’s RSI (14)?
25K0’s RSI (14) is 47.92, which suggests 25K0 is a Neutral.
What is 25K0’s MACD?
25K0’s MACD is -0.18, which suggests 25K0 is a Sell.
What is 25K0’s 5-day moving average?
25K0’s 5-day moving average is 0.52, which suggests 25K0 is a Buy.
What is 25K0’s 20-day moving average?
25K0 20-day moving average is 0.45, which suggests 25K0 is a Buy.
What is 25K0’s 50-day moving average?
25K0’s 50-day moving average is 1.03, which suggests 25K0 is a Sell.
What is 25K0’s 200-day moving average?
25K0’s 200-day moving average is 5.00, which suggests 25K0 is a Sell.
What is 25K0’s Williams % R (14)?
25K0’s Williams % R (14) is -13.77, which suggests 25K0 is a Sell.
What is 25K0’s CCI (14)?
25K0’s CCI (14) is 137.38, which suggests 25K0 is a Sell.
What is the share price of Karyopharm Therapeutics?
Karyopharm Therapeutics's share price is N/A€.
